Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 977
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 493
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 370
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Florian A. Lempp, Leah Soriaga, Martin Montiel-Ruiz, et al.
Nature (2021) Vol. 598, Iss. 7880, pp. 342-347
Closed Access | Times Cited: 293
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, et al.
Cochrane library (2021) Vol. 2021, Iss. 9
Open Access | Times Cited: 134
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Sanjeev Kumar, Anmol Chandele, Amit Sharma
PLoS Pathogens (2021) Vol. 17, Iss. 9, pp. e1009885-e1009885
Open Access | Times Cited: 97
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Juan Pablo Díaz Martinez, et al.
BMJ (2021), pp. n2231-n2231
Open Access | Times Cited: 75
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 38
Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis
Anselm Jorda, Manuel Kussmann, Nebu Kolenchery, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 36
In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein
Nabarun Chandra Das, Pritha Chakraborty, Jagadeesh Bayry, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 35
Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
Ahmed A. Al‐Karmalawy, Raya Soltane, Ayman Abo Elmaaty, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1317-1317
Open Access | Times Cited: 39
COVID-19 Drug Development
Seungtaek Kim
Journal of Microbiology and Biotechnology (2021) Vol. 32, Iss. 1, pp. 1-5
Open Access | Times Cited: 36
Treatments for COVID-19: Lessons from 2020 and new therapeutic options
Fanny Salasc, Thomas Lahlali, Emilie Laurent, et al.
Current Opinion in Pharmacology (2021) Vol. 62, pp. 43-59
Open Access | Times Cited: 33
Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
Eugenia Quirós-Roldán, Silvia Amadasi, Isabella Zanella, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 12, pp. 1272-1272
Open Access | Times Cited: 29
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Aline Almeida-Oliveira, Diana Freire, A. Andrade, et al.
Journal of Pharmaceutical Innovation (2023) Vol. 18, Iss. 3, pp. 1194-1212
Open Access | Times Cited: 11
Outpatient regimens to reduce COVID-19 hospitalisations: a systematic review and meta-analysis of randomized controlled trials
David J. Sullivan, Daniele Focosi, Daniel F. Hanley, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 16
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Qinglin Cheng, Chen Jun-fang, Qingjun Jia, et al.
Aging (2021) Vol. 13, Iss. 18, pp. 21866-21902
Open Access | Times Cited: 22
Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
Santiago Moreno, Bernardino Alcázar Navarrete, Carlos Dueñas, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 827-841
Open Access | Times Cited: 15
Identification and Development of Therapeutics for COVID-19
Halie M. Rando, Nils Wellhausen, Soumita Ghosh, et al.
mSystems (2021) Vol. 6, Iss. 6
Open Access | Times Cited: 19
The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
Immunopharmacology and Immunotoxicology (2021) Vol. 44, Iss. 1, pp. 28-34
Open Access | Times Cited: 18
Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop
Eloise Williams, Kathrine Craig, Christopher Chiu, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3484-3489
Open Access | Times Cited: 12
Effect of the Neutralizing SARS-CoV-2 Antibody Sotrovimab in Preventing Progression of COVID-19: A Randomized Clinical Trial
Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 15
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
Pooya Farhangnia, Shiva Dehrouyeh, Amir Reza Safdarian, et al.
International Immunopharmacology (2022) Vol. 109, pp. 108786-108786
Open Access | Times Cited: 10
Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab
David Totschnig, Daniel Doberer, Renate Haberl, et al.
IDCases (2022) Vol. 29, pp. e01528-e01528
Open Access | Times Cited: 10
Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles
Anthony D. Bai, Yunbo Jiang, David Nguyen, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2253301-e2253301
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top